Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

被引：20
|
作者：
Uckun, Fatih M. [1 ,2 ]
Qazi, Sanjive [3 ]
机构：
[1] Childrens Hosp Los Angeles, Dev Therapeut Program, Inst Pediat Clin Res, Los Angeles, CA 90027 USA
[2] Univ So Calif, Dept Pediat, Div Hematol Oncol, Sch Med,Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
[3] Gustavus Adolphus Coll, St Peter, MN 56082 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 09期
关键词：
leukemia; lymphoma; nanotechnology; rational drug design; RNA interference; spleen tyrosine kinase; tyrosine kinase inhibitor; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL ANTIGEN RECEPTOR; CHILDRENS-ONCOLOGY-GROUP; PRIMARY CLONOGENIC BLASTS; NON-HODGKIN-LYMPHOMA; BONE-MARROW RELAPSE; B-CELLS; PHOSPHOINOSITIDE; 3-KINASE; APOPTOTIC RESISTANCE; THERAPEUTIC TARGET;
D O I：
10.1586/ERA.10.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Spleen tyrosine kinase (SYK) has emerged as a potential molecular target for the treatment of B-lineage leukemias and lymphomas. Here, we provide an overview of the current state of knowledge regarding the regulatory signaling function of SYK and its role in the pathogenesis of B-lineage lymphoid malignancies, available methods and drug candidates for targeting SYK, as well as compelling preclinical and clinical evidence regarding the clinical potential of inhibiting SYK. The further development of rationally designed SYK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias and lymphomas.
引用
收藏
页码：1407 / 1418
页数：12
相关论文
共 50 条
  • [1] Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity
    Uckun, Fatih M.
    Qazi, Sanjive
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (11) : 1457 - 1470
  • [2] FLT3 tyrosine kinase as a target in acute leukemias
    Griffin, JD
    HEMATOLOGY JOURNAL, 2004, 5 : S188 - S190
  • [3] Getting Syk: spleen tyrosine kinase as a therapeutic target
    Geahlen, Robert L.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2014, 35 (08) : 414 - 422
  • [4] Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients
    Braegelmann, Christine
    Hoelzel, Michael
    Ludbrook, Valerie
    Dickson, Marion
    Turan, Nil
    Ferring-Schmitt, Sandra
    Sternberg, Sonja
    Bieber, Thomas
    Kuhn, Annegret
    Wenzel, Joerg
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (05) : 375 - 379
  • [5] Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients
    Braegelmann, C.
    Hoelzel, M.
    Ludbrook, V.
    Dickson, M.
    Turan, N.
    Ferring-Schmitt, S.
    Sternberg, S.
    Bieber, T.
    Kuhn, A.
    Wenzel, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 6 - 6
  • [6] Molecular biology of hematopoiesis and treatment of leukemias and lymphomas - Preface
    Abraham, NG
    Zander, A
    ACTA HAEMATOLOGICA, 1998, 99 (03) : 115 - 115
  • [7] Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection
    Alhazmi, Alaa
    JOURNAL OF INNATE IMMUNITY, 2018, 10 (04) : 255 - 263
  • [8] TYROSINE KINASE AS TARGET FOR CANCER TREATMENT
    Bedada, Abdisa Tufa
    Gayesa, Reta Tsegaye
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2014, 5 (01): : 1 - 15
  • [9] Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis
    Nijjar, Jagtar Singh
    Tindell, Alistair
    McInnes, Iain B.
    Siebert, Stefan
    RHEUMATOLOGY, 2013, 52 (09) : 1556 - 1562
  • [10] Inhibition of spleen tyrosine kinase as treatment of postoperative ileus
    van Bree, Sjoerd H. W.
    Gomez-Pinilla, Pedro Julian
    van de Bovenkamp, Fleur Suzanne
    Di Giovangiulio, Martina
    Farro, Giovanna
    Nemethova, Andrea
    Cailotto, Cathy
    de Jonge, Wouter J.
    Lee, Kevin
    Ramirez-Molina, Cesar
    Lugo, Dave
    Skynner, Michael J.
    Boeckxstaens, Guy E. E.
    Matteoli, Gianluca
    GUT, 2013, 62 (11) : 1581 - 1590
12345